Nyquist gives utilities, technology providers and equipment manufacturers access to selected technologies from Reactive Technologies’ patented Edge-to-Cloud AI foundation, helping partners reduce development complexity and bring advanced grid solutions to market faster through flexible licensing, integration and co-development.

LONDON, Sept. 29, 2026 /PRNewswire/ — Reactive Technologies today announced the launch of Nyquist, a new technology partnership programme that opens access to selected technologies and expertise developed through the company’s work with power system operators and utilities worldwide.

Nyquist enables partners to build advanced measurement and intelligence capabilities directly into their own products and applications, avoiding the need to develop complex sensing, signal-processing and analytical technologies from the ground up.

The rise of inverter-based resources, battery storage, data centres and other power-electronic loads is making power systems increasingly dynamic, making higher-resolution measurement, faster processing and more sophisticated analysis increasingly essential to maintaining grid stability and reliability.

Through Nyquist, partners can access and integrate technologies from Reactive Technologies’ patented Edge-to-Cloud AI foundation, spanning high-fidelity measurement and waveform capture, precise time-synchronisation, digital signal processing, edge AI, connectivity, data infrastructure and grid analytics. These technologies are already successfully deployed with leading utilities worldwide, helping them understand their power system like never before and confidently respond to the rapid growth of inverter-based resources and large-load connections. The programme extends the reach of these technologies through partnership, accelerating their adoption and impact across the industry.

“We are continually approached by organisations looking to collaborate with us, and now Nyquist offers a structured way to do that ” said Marc Borrett, CEO of Reactive Technologies. “Nyquist allows our strategic partners to build on the core technologies and expertise we have developed over many years, while retaining the flexibility to create solutions that fit their own customers, markets and applications.”

To learn more about Nyquist, please visit:

https://reactive-technologies.com/nyquist/

About Reactive Technologies 

Reactive Technologies is a global Grid-Enhancing Technologies (GETs) company addressing the challenges of energy transition, electrification and accelerating load growth.

With the proven GridVerix® platform, Reactive Technologies provides real-time, data-driven insights into grid stability and reliability, underpinned by grounded measurement and delivered through a data-as-a-service model. This enables grid operators, utilities and asset owners worldwide to plan and operate with greater visibility, efficiency and resilience as the grid continues to evolve.

For more information, visit reactive-technologies.com.  

View original content:https://www.prnewswire.com/news-releases/reactive-technologies-launches-nyquist-licensing-programme-to-accelerate-grid-innovation-through-technology-partnerships-302889344.html

SOURCE Reactive Technologies

The aggregate cover increases thirtyfold from USD 1 million, applies to available balances and open positions in the event of insolvency, and remains free to clients.

PORT LOUIS, Mauritius, Sept. 28, 2026 /PRNewswire/ — Startrader Financial Markets Limited (Mauritius) has raised the aggregate limit of its client fund insurance, underwritten by Arch and other Lloyd’s of London syndicates, from USD 1 million to USD 30 million, effective October 1, 2026. The policy covers available balances and collateral supporting open positions, responding above a per-client retention where insolvency coincides with covered misconduct.

Client fund protection increasingly shapes broker choice. Because insolvency is remote, cover size often goes unexamined until it matters, making early action a governance decision, not a marketing one.

The policy covers only eligible clients of this entity, not other STARTRADER entities, and complements its segregation of client funds from company assets.

“Insurance is not something clients think about on a good day. It matters on the worst one, and a ceiling that only looks adequate until it is tested is not much of a ceiling.”
–  Peter Karsten, CEO, STARTRADER

The higher limit will apply automatically from October 1, 2026, with no action required. Claims must be submitted to the appointed insolvency practitioner, with an Investor Compensation Claim Form, within 12 months of the insolvency event.

About STARTRADER

STARTRADER is a global multi-asset broker empowering retail and institutional partners to access global markets through a range of platforms, including MetaTrader, STARTRADER APP, and STAR Copy. Regulated in five jurisdictions (CMA, ASIC, FSCA, FSA, and FSC), STARTRADER combines strong governance with a client-first approach, serving both retail clients and partners with a commitment to transparency, reliability, and long-term growth.

Disclaimer: This announcement is for information only and is not investment advice or tailored to your circumstances. Forward-looking statements cannot be guaranteed. The insurance is an excess-of-loss policy subject to its full terms, conditions and exclusions, which prevail in any conflict. It covers only loss of client cash or securities caused by covered misconduct following an insolvency event, not trading losses. Payments may be less than a client’s loss and depend on the insolvency practitioner’s determinations and the firm’s policy compliance. Clients are beneficiaries of a discretionary trust with no direct claim against the insurer. CFDs are high risk and may not suit all investors. Not intended for distribution where contrary to local law or regulation.

View original content to download multimedia:https://www.prnewswire.com/news-releases/startrader-raises-lloyds-of-london-client-fund-insurance-to-usd-30-million-in-aggregate-302892609.html

SOURCE STARTRADER

SAN FRANCISCO and SUZHOU, China, Sept. 29, 2026 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of innovative medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced updated Phase 1 clinical data for IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA, and CD3, in patients with relapsed or refractory multiple myeloma (R/R MM) in an oral presentation at the 23rd International Myeloma Society (IMS) Annual Meeting 2026. Based on the results of the Phase 1 dose optimization study, the recommended Phase 2 dose (RP2D) of IBI3003 was determined to be 360 μg/kg. At the RP2D, IBI3003 demonstrated rapid, deep, and durable response signals, particularly in heavily pretreated, high-risk patients with extramedullary disease.

IBI3003 is a novel trispecific antibody targeting G protein-coupled receptor C5D (GPRC5D), B-cell maturation antigen (BCMA), and CD3. Its dual-targeting design against BCMA and GPRC5D is intended to overcome tumor escape caused by the loss or downregulation of a single tumor antigen. In preclinical mouse models, IBI3003 demonstrated superior in vivo anti-tumor activity compared with marketed benchmark bispecific antibodies targeting GPRC5D/CD3 or BCMA/CD3, with particularly prominent tumor-killing activity in in vitro cell models with low expression of BCMA and GPRC5D. Currently, Innovent is conducting Phase 1/2 clinical trials of IBI3003 in China, Australia, and the United States (NCT06083207 and NCT07336472) to evaluate its safety, tolerability, and preliminary efficacy in patients with R/R MM. In parallel, Innovent has advanced the Phase 3 TriadicMM-1 study (NCT07623798) in China for IBI3003 in patients with R/R MM who have received 1 to 4 prior lines of therapy. ‌ In addition, the Phase II study of IBI3003 combined with CD38 monoclonal antibody for frontline MM is also ongoing (NCT07764861).

The updated data were from the Phase 1 clinical study NCT06083207, which enrolled eligible patients with R/R MM who had failed at least two prior lines of therapy, including at least one proteasome inhibitor (PI), one immunomodulatory drug (IMiD), and one anti-CD38-based therapy, and who had relapsed or were refractory to their last anti-myeloma regimen. Patients with prior BCMA- and/or GPRC5D-targeted therapy were also eligible for enrollment. IBI3003 was administered subcutaneously once weekly (QW). Patients who received continuous treatment for ≥6 months and achieved a partial response (PR) or better for ≥2 months could switch to once-every-two-weeks (Q2W) dosing for maintenance. To reduce the risk of cytokine release syndrome (CRS), 1 to 3 priming doses were incorporated into the study design.

A total of 102 patients were enrolled in this phase of the study in China and Australia, with doses ranging from 0.1 μg/kg to 800 μg/kg. The median patient age was 62 years (range: 40-88), 37.1% of patients were classified as high risk according to mSMART criteria, and 53.9% had ≥1 site of extramedullary disease (EMD). The median number of prior lines of therapy was 4 (range: 2-12). All patients had received at least three classes of therapy, including a PI, an IMiD, and an anti-CD38 antibody. Among them, 55.9% had received at least five classes of therapy, including at least two PIs, two IMiDs, and one anti-CD38 antibody; 33.3% had previously received anti-BCMA and/or anti-GPRC5D therapies; and 88.2% were refractory to their last treatment. As of the data cutoff date of June 30, 2026, the median follow-up duration was 6.65 months (range: 0.8-15.2).

Rapid, Deep, and Durable Responses Observed with IBI3003 at 360 μg/kg

Based on an integrated analysis of the efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) data from dose optimization cohorts receiving IBI3003 at 120, 360, and 540 μg/kg in the Phase 1 study, the RP2D was determined to be 360 μg/kg.

A total of 26 patients received IBI3003 at 360 μg/kg, with a median follow-up duration of 7.57 months. mPFS was not reached yet.

The overall response rate (ORR) was 84.6%, including 11 cases of stringent complete response (sCR), 4 cases of very good partial response (VGPR), and 7 cases of partial response (PR). The ORR was 94.7% among 19 patients who had received 2 to 4 prior lines of therapy, 87.5% among 8 patients with non-bone-related EMD, and 92.3% among 13 patients without EMD.The median time to first response was 0.99 months (range: 0.9-8.3 months), the median time to first response of ≥VGPR was 1.87 months (range: 0.9-4.6 months), and the median time to first response of ≥CR was 2.79 months (range: 0.9-9.2 months).Among patients who achieved CR or better as assessed by central laboratory next-generation sequencing (NGS) testing, the minimal residual disease (MRD) negativity rate was 100% (n=8). Three patients achieved MRD negativity after receiving only one treatment cycle.

Manageable Safety Profile of IBI3003 in Patients with R/R MM

Hematologic toxicities were the most common Grade ≥3 treatment-related adverse events (TRAEs), occurring primarily during the dose-escalation phase and being manageable and reversible.The incidences of CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) were 52% and 3.9%, respectively. All events were Grade 1-2 and resolved with treatment. Prophylactic use of tocilizumab may reduce the risk of CRS.The incidence of infections was 42.2%, with Grade ≥3 infections reported in 26.5% of patients.For GPRC5D target-related TEAEs involving the oral cavity, skin, and nails, no Grade ≥3 oral TEAEs were observed. Most skin and nail TEAEs were Grade 1-2, with only two patients experiencing Grade 3 rash.

Potent and Sustained Pharmacodynamic Responses Observed with IBI3003 in Patients with R/R MM

Biomarker analyses showed a significant and sustained decline in serum soluble BCMA (sBCMA) levels across the IBI3003 120 μg/kg, 360 μg/kg, and 540 μg/kg dose groups.Deep and durable reductions in sBCMA levels were observed across all dose groups. After three treatment cycles, the median reduction from baseline in sBCMA levels was 98.38% in the IBI3003 360 μg/kg group.

IBI3003 continued to demonstrate encouraging and durable responses, together with a manageable safety profile, in heavily pretreated patients with R/R MM. These efficacy and safety data support further evaluation of the clinical value of IBI3003 in the ongoing Phase 3 clinical study.

Professor Peng Liu of Zhongshan Hospital Affiliated to Fudan University stated, “Patients with R/R MM have a poor prognosis after failing treatments including PIs, IMiDs, and anti-CD38-based therapies, with an ORR of only 29.8%, a median progression-free survival of 4.6 months, and a median overall survival of 12.4 months[1]. Although bispecific antibodies are reshaping the treatment landscape of R/R MM, trispecific antibodies targeting two antigens simultaneously may help overcome treatment resistance caused by intra-tumor and inter-tumor heterogeneity, as well as treatment-induced antigen escape. A substantial unmet clinical need remains in R/R MM, particularly among heavily pretreated and high-risk patients.

The dual-target coverage of BCMA and GPRC5D by IBI3003 addresses antigen expression heterogeneity and treatment resistance associated with single-target therapies, thereby reducing tumor escape. Its optimized CD3 affinity enables precise T-cell activation and tumor killing while improving safety. In the Phase 1 results presented at this meeting, IBI3003 demonstrated a manageable safety profile and impressive efficacy at the 360 μg/kg dose, with an ORR of 84.6%. Significant efficacy was also observed in patients with EMD or other high-risk features, fully demonstrating the potential of IBI3003 to overcome treatment resistance. The ORR reached 94.7% among patients who had received 2 to 4 prior lines of therapy. We look forward to the results of the ongoing Phase 3 clinical study of IBI3003.”

About IBI3003 (Anti-GPRC5D/BCMA/CD3 Trispecific Antibody)

IBI3003 was developed using Innovent’s proprietary Sanbody® platform. It is a novel trispecific antibody targeting G protein-coupled receptor C5D (GPRC5D), B-cell maturation antigen (BCMA), and CD3. The molecule was designed to overcome tumor escape caused by the loss or downregulation of a single tumor antigen. In preclinical mouse models, IBI3003 demonstrated superior in vivo anti-tumor activity compared with marketed benchmark bispecific antibodies. It also demonstrated particularly prominent tumor-killing activity in in vitro cell models with low expression of BCMA and GPRC5D.

Phase 1/2 clinical trials of IBI3003 (NCT06083207 and NCT07336472) are being conducted concurrently in China, Australia, and the United States to evaluate its safety, tolerability, and efficacy in patients with R/R MM. In China, IBI3003 has advanced into a pivotal registrational clinical stage. TriadicMM-1 (NCT07623798) is a multicenter, randomized, open-label Phase 3 study designed to compare the efficacy and safety of IBI3003 with investigator’s choice of therapy in patients with R/R MM who have received 1 to 4 prior lines of therapy. The primary endpoint is progression-free survival (PFS) assessed by an independent review committee (IRC). In addition, the Phase II study of IBI3003 combined with CD38 monoclonal antibody for frontline MM is also ongoing (NCT07764861).

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 20 products in the market. It has 1 asset under NMPA review, 5 assets in phase 3 or pivotal clinical trials, and 20 more molecules in early clinical stage.

Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion. These efforts have set a benchmark for the high-quality outbound internationalization of China’s innovative drug industry.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible.

For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:
1) Innovent does not recommend the use of any unapproved drug (s)/indication (s).
2) Ramucirumab (Cyramza®) and selpercatinib (Retsevmo®), pirtobrutinib (Jaypirca®) and abemaciclib (Verzenios®) were developed by Eli Lilly and Company.
Disclaimer: Innovent does not recommend any off-label usage.

Forward-Looking Statements of Innovent Biologics

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

View original content:https://www.prnewswire.com/news-releases/2026-ims-oral-presentation-innovent-announces-updated-phase-1-clinical-data-of-trispecific-antibody-ibi3003-gprc5dbcmacd3-in-patients-with-relapsed-or-refractory-multiple-myeloma-302892611.html

SOURCE Innovent Biologics